Oramed Pharmaceuticals Inc (ORMP)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK, NY 10036

Oramed Pharmaceuticals, Inc., a development stage company, engages in the research and development of pharmaceutical solutions. The company is developing orally ingestible insulin pill capsules for the treatment of individuals with diabetes. It also focuses on conducting research and development of other pharmaceutical solutions, including rectal application of insulin, flu vaccines, use of oral ingestible pills for delivery other polypeptides, and use of rectal application for delivery of other polypeptides. Oramed Pharmaceuticals, Inc., a development stage company, engages in the research and development of pharmaceutical solutions. The company is developing orally ingestible insulin pill capsules for the treatment of individuals with diabetes. It also focuses on conducting research and development of other pharmaceutical solutions, including rectal application of insulin, flu vaccines, use of oral ingestible pills for delivery other polypeptides, and use of rectal application for delivery of other polypeptides. Oramed Pharmaceuticals, Inc., a development stage company, engages in the research and development of pharmaceutical solutions. The company is developing orally ingestible insulin pill capsules for the treatment of individuals with diabetes. It also focuses on conducting research and development of other pharmaceutical solutions, including rectal application of insulin, flu vaccines, use of oral ingestible pills for delivery other polypeptides, and use of rectal application for delivery of other polypeptides.

Data as of 2021-05-08 10:48:13 -0400
Market Cap330.699 Million Shares Outstanding30.228 Million Avg 30-day Volume416.735 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-15.37 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.46796 52-week High/Low12.73 / 2.4 Next Earnings Date2021-07-07 Price to Cash FLow (P/CF) -43.1937
Data provided by IEX Cloud
View SEC Filings from ORMP instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 38 35 8.57% 11 (0.66%) 8 (0.5%) 37.5%
13F shares: 878.326 Thousand 1.428 Million -38.48% 555.207 Thousand 691.12 Thousand -19.67%
% Ownership 3.7098 6.0685 -38.87% 2.3451 2.9376 -20.17%
New Positions: 11 6 83.33% 5 3 66.67%
Increased Positions 4 10 -60.0% 1 1 0.0%
Closed Positions 8 6 33.33% 2 2 0.0%
Reduced Positions 9 5 80.0% 2 1 100.0%
Total Calls 137.964 Thousand 23.424 Thousand 488.99% 41 Thousand 0
Total Puts 17.995 Thousand 0 16.291 Thousand 0
PUT/CALL Ratio 0.13 0.0 0.4
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ORMP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ORMP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SANK LEONARD

  • Director
138,889 2021-02-26 1

RAKIN KEVIN

  • Director
0 2021-02-17 1

KIDRON MIRIAM CHIEF SCIENTIFIC OFFICER

  • Officer
  • Director
0 2021-02-03 1

HEXTER JOSHUA COO, BUSINESS OFFICER

  • Officer
0 2021-02-03 1

KIDRON NADAV PRESIDENT AND CEO

  • Officer
  • Director
  • 10% Owner
0 2021-02-03 1

GABAY AVRAHAM CFO, TREASURER AND SECRETARY

  • Officer
0 2021-02-03 1

FRIEDMAN AVIAD

  • Director
0 2020-01-08 0

XIAOMING GAO

  • Director
0 2020-01-08 0

MAYER ARIE

  • Director
0 2020-01-08 0

SLAGER DAVID MARK

  • Director
0 2019-04-15 0

EISENBERG HILLA CFO, TREASURER AND SECRETARY

  • Officer
0 2019-02-26 0

HASLETON MARK DANIEL VP BUSINESS DEVELOPMENT

  • Officer
0 2019-02-26 0

LI XIAOPENG

  • Director
206,350 2017-08-02 0

ZOMMER YIFAT HEN CFO, TREASURER AND SECRETARY

  • Officer
0 2017-06-30 0

LAW RONALD EDWARD CHIEF STRATEGY OFFICER

  • Officer
0 2017-03-20 0

JACOB HAROLD

  • Director
17,096 2016-03-10 0

REGALS CAPITAL MANAGEMENT LP

  • 10% Owner
1,186,823 2015-12-23 0

BERELOWITZ MICHAEL

  • Director
22,896 2015-12-09 0

REGALS CAPITAL MANAGEMENT LP

REGALS FUND LP

SLAGER DAVID MARK

  • 10% Owner
896,364 2015-10-16 0

OSTROV GERALD M

  • Director
24,896 2015-02-23 0

BRONFELD ZEEV

  • 10% Owner
6,589,767 2011-09-27 0

ORLEV CHAIME CFO, TREASURER AND SECRETARY

  • Officer
No longer subject to file 2009-04-22 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ORAMED PHARMACEUTICALS INC ORMP 2021-05-13 17:15:03 UTC -9.9843 10.0343 350000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-13 16:45:03 UTC -10.083 10.133 350000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-13 16:15:02 UTC -10.083 10.133 350000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-13 15:45:03 UTC -10.083 10.133 350000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-13 15:15:03 UTC -10.083 10.133 350000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-13 14:45:02 UTC -9.1706 9.2206 400000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-13 14:15:03 UTC -9.1706 9.2206 400000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-13 13:45:02 UTC -9.1706 9.2206 400000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-13 13:15:03 UTC -9.1706 9.2206 400000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-13 12:45:03 UTC -9.1706 9.2206 400000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-12 22:15:03 UTC -9.1706 9.2206 450000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-12 21:45:02 UTC -9.1928 9.2428 450000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-12 21:15:03 UTC -9.1928 9.2428 450000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-12 20:45:03 UTC -9.1928 9.2428 450000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-12 20:15:04 UTC -9.1928 9.2428 450000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-12 19:45:03 UTC -9.1928 9.2428 450000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-12 19:15:03 UTC -9.1928 9.2428 450000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-12 18:45:03 UTC -9.1928 9.2428 450000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-12 18:15:03 UTC -9.1928 9.2428 450000
ORAMED PHARMACEUTICALS INC ORMP 2021-05-12 17:45:03 UTC -9.1928 9.2428 450000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments